Table 1.
Baseline demographic characteristics for the safety population, phases 1 and 2 combined
| 3 μg group | 6 μg group | Placebo group | Overall | ||
|---|---|---|---|---|---|
| Days 0 and 14 vaccination cohorts, pooled | |||||
| Participants | 144 | 144 | 84 | 372 | |
| Sex | |||||
| Female | 77 (53%) | 86 (60%) | 44 (52%) | 207 (56%) | |
| Male | 67 (47%) | 58 (40%) | 40 (48%) | 165 (44%) | |
| Han nationality | 144 (100%) | 144 (100%) | 84 (100%) | 372 (100%) | |
| Age, years | 42·4 (10·2) | 42·8 (9·0) | 42·4 (8·8) | 42·6 (9·4) | |
| Days 0 and 28 vaccination cohorts, pooled | |||||
| Participants | 144 | 144 | 83 | 371 | |
| Sex | |||||
| Female | 75 (52%) | 70 (49%) | 45 (54%) | 190 (51%) | |
| Male | 69 (48%) | 74 (51%) | 38 (46%) | 181 (49%) | |
| Han nationality | 144 (100%) | 144 (100%) | 83 (100%) | 371 (100%) | |
| Age, years | 41·8 (9·4) | 41·2 (10·2) | 44·1 (9·1) | 42·1 (9·7) | |
Data are n, n (%), or mean (SD).